A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PU / particle units

[Related PubMed/MEDLINE]
Total Number of Papers: 18
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PU  (>> Co-occurring Abbreviation)
Long Form:   particle units
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. ---
2016 Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). AEs, APTT, EnvA, rAd35
2016 Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. ChAd3-EBO-Z, MK
2013 DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. IM, N/S
2012 EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. 5-FU, LAPC, TNF-alpha
2012 Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. OS, pCR
2010 Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge. Abs, Ad, scFv
2010 Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. IFN-gamma, rAd5
2006 Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. AMD
10  2006 Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. AdVEGF121
11  2006 Repeated administration of adenovector in the eye results in efficient gene delivery. Ad, IM, IVT, PO
12  2005 Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Ad, AdC7PA, PA
13  2005 Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. LINCL, TPP-I
14  2004 TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. ---
15  2002 Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Ad, CAD, CF, IL-6, PVD, VEGF
16  2002 TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. TNF-alpha
17  2001 Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals. Ad, ELF
18  1999 Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. Ad, Ad5, CF